Related Experiment Video
Updated: May 6, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Management of hormone-sensitive metastatic prostate cancer
1Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Suite 2123, Salt Lake City, UT 84112, USA.
Abstract:
Targeting gonadal androgen synthesis (often in conjunction with blockade of androgen receptor) is the cornerstone of treatment of hormone-sensitive metastatic prostate cancer (HSPC). Despite the failure of androgen deprivation therapy, most tumors maintain some dependence on androgen or androgen receptor signaling for proliferation. This article reviews the current standard of care for metastatic HSPC, mechanisms of treatment resistance, novel drugs targeting the androgen signaling pathway, biomarkers predicting response to treatment and survival, future directions, and ongoing clinical trials in HSPC.
Insights
This review covers hormone-sensitive metastatic prostate cancer (HSPC) treatments, focusing on androgen deprivation therapy and resistance mechanisms. It also explores novel drugs and biomarkers for improved patient outcomes in HSPC.
Area of Science:
- Oncology
- Endocrinology
- Urology
Background:
- Hormone-sensitive metastatic prostate cancer (HSPC) treatment relies on targeting androgen synthesis and androgen receptor signaling.
- Tumor cells often retain dependence on androgen signaling despite initial treatment failure.
Purpose of the Study:
- To review the current standard of care for metastatic HSPC.
- To discuss mechanisms of treatment resistance.
- To highlight novel drugs, biomarkers, and future directions in HSPC research.
Main Methods:
- Literature review of current standards of care for metastatic HSPC.
- Analysis of mechanisms driving resistance to androgen deprivation therapy.
- Examination of emerging therapeutic strategies targeting the androgen signaling pathway.
- Review of biomarkers for predicting treatment response and survival.
Main Results:
- Androgen deprivation therapy is the cornerstone of HSPC treatment.
- Resistance to therapy is common, with tumors often maintaining androgen receptor signaling dependence.
- Novel drugs and targeted therapies are emerging to overcome resistance.
- Biomarkers are crucial for predicting treatment efficacy and patient survival.
Conclusions:
- Effective management of HSPC requires understanding resistance mechanisms.
- Novel therapeutic strategies targeting the androgen signaling pathway offer promise for improved outcomes.
- Biomarker identification is essential for personalized treatment approaches in HSPC.
